Markets sutable for buccal extended release technology

nightmares of PTSD patients

PTSD affects 6–8% globally.
80% of patients suffer from nightmares & sleep disorders.
No approved drugs exist.
Current treatments (SSRIs, antipsychotics, adrenergic drugs) have severe side effects, addiction risk, and limited efficacy.

Lasting Effect Solution

Buccal mucoadhasive extended-release tablet designed for night use.
Repurposing existing alpha-1 adrenergic receptor blockers
Maintains therapeutic drug levels throughout sleep, solving the short duration problem of oral drugs

Sjogren syndrome treatment Tablet

An autoimmune disease that affects the exocrine secretion glands (saliva, tears, etc.). The treatment with cholinergic agonists have side effects. The cholinergic agonists activate receptors on the salivary glands and cause saliva secretion. There is an advantage to administering the drug in a prolonged manner and the buccal administration will allow for a dose reduction and a significant reduction of the side effects

Antiviral viruses preventive tablet

Currently, the main preventive measure against infection from SARS-CoV-2 and other airborne viruses are masks covering the nose and mouth. This practice continues from the 14 century.

Lasting Effect has developed a new prototype formulation based on an antiviral natural ingredient packed into an extended-release tablet.

The antiviral ingredients are with typical volatile properties. Their vapors are safe and do not harm epithelial cells and therefore are qualified as GRAS (generally recognized as safe) by the FDA.

The efficacy of the antiviral ingredients was successfully demonstrated against SARS-Cov2 virus at the Clinical Microbiology and Infectious Diseases Laboratory.

The formulations tested in vitro on VERO cells have a significant inhibitory effect on SARS-Cov2 replication.